The Toll-like Receptor Ligand, CpG Oligodeoxynucleotides, Regulate Proliferation and Osteogenic Differentiation of Osteoblast

Overview

Journal J Orthop Surg Res

Publisher Biomed Central

Specialty Orthopedics

Date 2020 Aug 16

PMID 32795334

Citations 8

Authors

Wenwen Yu

Yi Zheng

Hongyan Li

Hongbing Lin

Zhen Chen

Yue Tian

Huishan Chen

Peipei Zhang

Xiaowei Xu

Yuqin Shen

Affiliations

Soon will be listed here.

Abstract

Background: This study aimed to investigate the regulation of CpG oligodeoxynucleotides (ODNs) on proliferation and osteogenic differentiation of MC3T3 cells.

Methods: The laser co-focusing and flow cytometry assay were employed to detect cell uptake of CpG ODN 2006. Twelve ODNs were sythesized, and their effects on proliferation and differentiation were detected by MTT and alkaline phosphatase (ALP) activity assay. Flow cytometry assay was used to examine the regulation of CpG ODN on cell cycle. Quantitative real-time PCR (qRT-PCR) and western blot were used to evaluate the regulation of CpG ODN on mRNA and protein expression of osteogenic differentiation genes.

Results: The phosphorothioate CpG ODN 2006 could efficiently enter the MC3T3 cells in 1 h and locate in the cytoplasm. The MTT assay demonstrated CpG ODNs could promote MC3T3 cell proliferation and differentiation in the early stage, and gradually attenuated along with the increase of treating time, except for BW001 and FC001. qRT-PCR assay demonstrated that all the 12 CpG ODNs could promote the relative expression level of osteogenic differentiated genes, SP7 and OCN. In addition, western blot analysis suggested the CpG ODNs of BW001 and FC001 could increase the protein expression of P27 and Runx2 and decrease the protein expression of cyclin D1.

Conclusion: The selected CpGODNs may be a potential gene therapy for bone regeneration of periodontitis.

Citing Articles

Osteogenic CpG Oligodeoxynucleotide, iSN40, Inhibits Osteoclastogenesis in a TLR9-Dependent Manner.

Ikeda R, Kimura C, Nihashi Y, Umezawa K, Shimosato T, Takaya T Life (Basel). 2025; 14(12.

PMID: 39768281 PMC: 11679607. DOI: 10.3390/life14121572.

The impact of hyaluronic acid coating on polyether ether ketone dental implant surface: An in vitro analysis.

Abdulghafor M, Mustafa Amin Z Saudi Dent J. 2024; 36(10):1326-1332.

PMID: 39525932 PMC: 11544272. DOI: 10.1016/j.sdentj.2024.07.012.

Correction: The Toll-like receptor ligand, CpG oligodeoxynucleotides, regulate proliferation and osteogenic differentiation of osteoblast.

Yu W, Zheng Y, Li H, Lin H, Chen Z, Tian Y J Orthop Surg Res. 2023; 18(1):823.

PMID: 37915026 PMC: 10621316. DOI: 10.1186/s13018-023-04295-2.

Relevant Properties and Potential Applications of Sericin in Bone Regeneration.

Kim J, Kim S, Garagiola U Curr Issues Mol Biol. 2023; 45(8):6728-6742.

PMID: 37623245 PMC: 10453912. DOI: 10.3390/cimb45080426.

Metal-polyDNA nanoparticles reconstruct osteoporotic microenvironment for enhanced osteoporosis treatment.

Liu X, Li F, Dong Z, Gu C, Mao D, Chen J Sci Adv. 2023; 9(31):eadf3329.

PMID: 37531423 PMC: 10396296. DOI: 10.1126/sciadv.adf3329.

References

Zhang H, Yan T, Xu S, Feng S, Huang D, Fujita M . Graphene oxide-chitosan nanocomposites for intracellular delivery of immunostimulatory CpG oligodeoxynucleotides. Mater Sci Eng C Mater Biol Appl. 2017; 73:144-151. DOI: 10.1016/j.msec.2016.12.072. View

Azuma M . Fundamental mechanisms of host immune responses to infection. J Periodontal Res. 2006; 41(5):361-73. DOI: 10.1111/j.1600-0765.2006.00896.x. View

Jakob T, Walker P, Krieg A, Udey M, Vogel J . Activation of cutaneous dendritic cells by CpG-containing oligodeoxynucleotides: a role for dendritic cells in the augmentation of Th1 responses by immunostimulatory DNA. J Immunol. 1998; 161(6):3042-9. View

Galindo M, Pratap J, Young D, Hovhannisyan H, Im H, Choi J . The bone-specific expression of Runx2 oscillates during the cell cycle to support a G1-related antiproliferative function in osteoblasts. J Biol Chem. 2005; 280(21):20274-85. PMC: 2895256. DOI: 10.1074/jbc.M413665200. View

Krieg A . Therapeutic potential of Toll-like receptor 9 activation. Nat Rev Drug Discov. 2006; 5(6):471-84. DOI: 10.1038/nrd2059. View

Komori T . Regulation of bone development and maintenance by Runx2. Front Biosci. 2007; 13:898-903. DOI: 10.2741/2730. View

Krieg A . CpG motifs: the active ingredient in bacterial extracts?. Nat Med. 2003; 9(7):831-5. DOI: 10.1038/nm0703-831. View

Qiao M, Shapiro P, Fosbrink M, Rus H, Kumar R, Passaniti A . Cell cycle-dependent phosphorylation of the RUNX2 transcription factor by cdc2 regulates endothelial cell proliferation. J Biol Chem. 2006; 281(11):7118-28. DOI: 10.1074/jbc.M508162200. View

Feng Z, Shen Y, Wang L, Cheng L, Wang J, Li Q . An oligodeoxynucleotide with promising modulation activity for the proliferation and activation of osteoblast. Int J Mol Sci. 2011; 12(4):2543-55. PMC: 3127133. DOI: 10.3390/ijms12042543. View

10.

Scheiermann J, Klinman D . Clinical evaluation of CpG oligonucleotides as adjuvants for vaccines targeting infectious diseases and cancer. Vaccine. 2014; 32(48):6377-89. PMC: 4252359. DOI: 10.1016/j.vaccine.2014.06.065. View

11.

Shen R, Wang X, Drissi H, Liu F, OKeefe R, Chen D . Cyclin D1-cdk4 induce runx2 ubiquitination and degradation. J Biol Chem. 2006; 281(24):16347-53. PMC: 2649830. DOI: 10.1074/jbc.M603439200. View

12.

Bauer S, Kirschning C, Hacker H, Redecke V, Hausmann S, Akira S . Human TLR9 confers responsiveness to bacterial DNA via species-specific CpG motif recognition. Proc Natl Acad Sci U S A. 2001; 98(16):9237-42. PMC: 55404. DOI: 10.1073/pnas.161293498. View

13.

Kim I, Yan X, Tohme S, Ahmed A, Cordon-Cardo C, Kumara H . CpG ODN, Toll like receptor (TLR)-9 agonist, inhibits metastatic colon adenocarcinoma in a murine hepatic tumor model. J Surg Res. 2011; 174(2):284-90. DOI: 10.1016/j.jss.2010.12.021. View

14.

Hou X, Shen Y, Zhang C, Zhang L, Qin Y, Yu Y . A specific oligodeoxynucleotide promotes the differentiation of osteoblasts via ERK and p38 MAPK pathways. Int J Mol Sci. 2012; 13(7):7902-7914. PMC: 3430211. DOI: 10.3390/ijms13077902. View

15.

Tane S, Ikenishi A, Okayama H, Iwamoto N, Nakayama K, Takeuchi T . CDK inhibitors, p21(Cip1) and p27(Kip1), participate in cell cycle exit of mammalian cardiomyocytes. Biochem Biophys Res Commun. 2014; 443(3):1105-9. DOI: 10.1016/j.bbrc.2013.12.109. View

16.

Komori T . Runx2, a multifunctional transcription factor in skeletal development. J Cell Biochem. 2002; 87(1):1-8. DOI: 10.1002/jcb.10276. View

17.

Hemmi H, Takeuchi O, Kawai T, Kaisho T, Sato S, Sanjo H . A Toll-like receptor recognizes bacterial DNA. Nature. 2000; 408(6813):740-5. DOI: 10.1038/35047123. View

18.

Kurreck J . Antisense technologies. Improvement through novel chemical modifications. Eur J Biochem. 2003; 270(8):1628-44. DOI: 10.1046/j.1432-1033.2003.03555.x. View

19.

Amcheslavsky A, Hemmi H, Akira S, Bar-Shavit Z . Differential contribution of osteoclast- and osteoblast-lineage cells to CpG-oligodeoxynucleotide (CpG-ODN) modulation of osteoclastogenesis. J Bone Miner Res. 2005; 20(9):1692-9. DOI: 10.1359/JBMR.050515. View

20.

Klinman D . Immunotherapeutic uses of CpG oligodeoxynucleotides. Nat Rev Immunol. 2004; 4(4):249-58. DOI: 10.1038/nri1329. View